Company Overview
20/20 Biolabs, Inc., operating under the trade name 20/20 GeneSystems, Inc., functions as a clinical laboratory testing company dedicated to cancer screening and viral testing services. The firm offers multi-cancer early detection blood testing, including a specific product line known as OneTest, alongside viral testing services such as rapid COVID-19 test kits. This entity operates within the Healthcare sector, specifically the Medical Devices industry, which implies a focus on biological diagnostics and medical infrastructure rather than hardware manufacturing. As a micro-cap entity, the company holds a market capitalization of $18.63M and generates annual revenue of $2.04M while employing 13 individuals. These valuation and revenue figures indicate that the company occupies a niche position in the market, characterized by significant operational scale limitations relative to established peers, yet it maintains a distinct presence in the specialized field of early detection diagnostics.
Financial Health
The company reported a revenue of $2.04M over the trailing twelve months, yet it posted a net income of -$3,255,098 and an EBITDA of -$3,138,820. The substantial gap between the $2.04M revenue and the negative net income reveals a cost structure where operating expenses and losses significantly outweigh gross earnings, resulting in a net loss exceeding three times the total revenue. While the company possesses $1.14M in cash reserves, it simultaneously carries $1.16M in debt, leaving it with negligible free cash flow as indicated by the N/A metric, which suggests limited financial flexibility to fund organic expansion without external capital. The gross margin stands at 32.1%, indicating that the company retains roughly one-third of revenue after the direct costs of generating its blood test and viral testing services. However, the operating margin is -191.4% and the profit margin is -159.3%, figures that demonstrate severe operational inefficiencies or high fixed costs relative to current sales volumes. The balance sheet is heavily leveraged, evidenced by a debt-to-equity ratio of 1069.38, meaning the company relies overwhelmingly on debt financing compared to shareholder equity. Liquidity is constrained, as the current ratio of 0.79 indicates that current liabilities exceed current assets, suggesting potential difficulty in meeting short-term obligations. Furthermore, Return on Equity and Return on Assets are listed as N/A due to the negative equity and asset bases, revealing that management has not yet generated positive returns on the capital invested in the business.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both N/A, a status that implies the company is not currently profitable and therefore cannot be valued based on earnings multiples, rendering traditional growth expectations difficult to quantify via standard P/E metrics. The price-to-book ratio is 150.00, a figure that indicates the market is pricing the stock at a massive premium over its book value, likely reflecting high expectations for future recovery or the unique nature of its intellectual property in cancer screening. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 9.12 and an EV/EBITDA of -2.84, suggesting the market is valuing the firm primarily on its revenue generation potential rather than its current cash flows or earnings. The 52-week high is $50.00 and the 52-week low is $1.68, placing the current trading price significantly closer to the low end of this volatile range and highlighting the asset's recent price compression. The beta is -0.42, a negative value that is anomalous for equities and suggests the stock price moves inversely to the broader market or exhibits extreme idiosyncratic volatility that deviates from standard correlation models.
Growth & Income
The company experienced a revenue growth of 15.8% year-over-year, while earnings growth is N/A because the firm remains in a loss position. Since earnings are negative, the concept of earnings growing faster or slower than revenue is inapplicable in traditional terms, though the positive revenue growth indicates successful expansion of its cancer screening and viral testing service offerings despite the lack of profitability. The company does not pay dividends, as the dividend yield is N/A and the payout ratio is 0.0%, which means the firm reinvests all available resources, including its $1.14M cash balance, back into operations rather than distributing income to shareholders. This profile characterizes 20/20 Biolabs, Inc. as a high-risk, growth-oriented venture that prioritizes scaling its laboratory testing business over providing immediate income returns to its investor base.